PROBLEM TO BE SOLVED: To provide a composition for treating NAFLD by increasing the level of n-3 PUFA in a patient with non-alcoholic fatty liver disease (NAFLD) without increasing the body load of PCB 153. A composition comprising at least 40% by weight of at least one of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) or derivatives thereof, wherein the amount of PCB 153 in the composition is less than 5.0 ng/g. Stuff. It is preferred that the composition further comprises an antioxidant such as mixed tocopherols. [Selection diagram] None【課題】PCB 153の体内負荷を増加させることなく、非アルコール性脂肪肝疾患(NAFLD)患者のn-3 PUFAのレベルを上昇させることにより、NAFLDを治療するための組成物の提供。【解決手段】少なくとも40重量％の、エイコサペンタエン酸(EPA)及びドコサヘキサエン酸(DHA)又はそれらの誘導体の少なくとも1種を含み、組成物中のPCB 153の量が5.0ng/g未満である組成物。前記組成物がさらに混合トコフェロール等の抗酸化物質を含むことが好ましい。【選択図】なし
